A congenial business environment is yet to be restored under the interim government, said Tapan Chowdhury, managing director of Square Pharmaceuticals.
Square Pharmaceuticals PLC registered a 9 percent year-on-year growth in profit to Tk 600 crore in July-September this year.
Square Pharmaceuticals Ltd clocked a Tk 1,491.01 crore profit in the July-March period of the ongoing financial year, up 4.9 per cent from a year earlier.
Drug maker Renata Ltd has secured approval from the US Food and Drug Administration (USFDA) for its general facility in Rajendrapur.
Square Pharmaceuticals Kenya EPZ Ltd, a subsidiary of Square Pharmaceuticals, has recently received a go-ahead to start commercial manufacturing in its Kenyan factory.
The company will manufacture and sell generic pharmaceutical medicine in Kenya and East African Community (EAC).
A congenial business environment is yet to be restored under the interim government, said Tapan Chowdhury, managing director of Square Pharmaceuticals.
Square Pharmaceuticals PLC registered a 9 percent year-on-year growth in profit to Tk 600 crore in July-September this year.
Square Pharmaceuticals Ltd clocked a Tk 1,491.01 crore profit in the July-March period of the ongoing financial year, up 4.9 per cent from a year earlier.
Drug maker Renata Ltd has secured approval from the US Food and Drug Administration (USFDA) for its general facility in Rajendrapur.
Square Pharmaceuticals Kenya EPZ Ltd, a subsidiary of Square Pharmaceuticals, has recently received a go-ahead to start commercial manufacturing in its Kenyan factory.
The company will manufacture and sell generic pharmaceutical medicine in Kenya and East African Community (EAC).
